Pathological response and efficacy of neoadjuvant carboplatine in early triple negative breast cancer

Authors

  • Nader Abdullah Tishreen University

Abstract

Several recent international studies showed that adding carboplatin to anthracyclines and taxanes improves the rate of complete pathological response in triple negative breast cancer This retrospective study aims to evaluate the role of carboplatin by adding it to taxanes (docetaxel, paclitaxel) in early triple-negative breast cancer patients treated with chemotherapy before surgery in terms of pathological response rate.

The study included 54 patients who attended the Chemotherapy and Radiotherapy Center in Tishreen Hospital between March 2016 and January 2020 with non-metastatic triple negative breast cancer (hormone receptor negative (ER-,PR-) and anti-membrane receptor 2 negative (HER2-)) with Tumor size ≥ 2 cm and/or clinically palpable lymph node enlargement. All patients were treated before surgery (4 doses of AC with 4 doses of carboplatin added to it (docetaxel/paclitaxel weekly or every three weeks).

A complete pathological response rate was observed in 25 patients ( 46.3%), partial pathological response in 24 patients ( 44.4%), while a progression in 5 patients with a rate of 9.3%. The response was better in postmenopausal women who had ductal carcinoma, with tumor size between (2-5 cm) and negative lymph nodes with a statistically significant difference.

The best combination was between carboplatin and weekly paclitaxel, where the complete pathological response occurred in 18 patients (72%), while the complete response occurred in 6 patients (24%) when carboplatin and docetaxel combined. The worst combination of carboplatin and paclitaxel every three weeks, with a complete pathological response in one patient  (4%) , without a statistically significant difference between the three protocols.

The addition of carboplatin to taxanes, especially weekly paclitaxel, is an important treatment option in patients with early triple negative breast cancer who are candidates for neo adjuvant chemotherapy.

Author Biography

Nader Abdullah, Tishreen University

Associate Professor - Department of Oncology - Faculty of Medicine

Downloads

Published

2021-10-28

How to Cite

1.
عبدالله ن. Pathological response and efficacy of neoadjuvant carboplatine in early triple negative breast cancer. Tuj-hlth [Internet]. 2021Oct.28 [cited 2024Nov.24];43(5). Available from: https://journal.tishreen.edu.sy/index.php/hlthscnc/article/view/11004

Issue

Vol. 43 No. 5 (2021): Tishreen University Journal for Research and Scientific Studies - Health Sciences Series

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

The authors retain the copyright and grant the right to publish in the magazine for the first time with the transfer of the commercial right to Tishreen University Journal for Research and Scientific Studies - Health Sciences Series

 Under a CC BY- NC-SA 04 license that allows others to share the work with of the work's authorship and initial publication in this journal. Authors can use a copy of their articles in their scientific activity, and on their scientific websites, provided that the place of publication is indicted in  Tishreen University Journal for Research and Scientific Studies - Health Sciences Series   .  The Readers have the right to send, print and subscribe to the initial version of the article, and the title of  Tishreen University Journal for Research and Scientific Studies - Health Sciences Series  Publisher

journal uses a CC BY-NC-SA license which mean

You are free to:

  • Adapt — remix, transform, and build upon the material
  •  
  • The licensor cannot revoke these freedoms as long as you follow the license terms.

 

  • Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  • NonCommercial — You may not use the material for commercial purposes.
  • ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
  • No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.